SkinMedica Appoints Mary Fisher Chief Executive Officer

SAN DIEGO--(Business Wire)--
SkinMedica, Inc. announced today that Mary M. Fisher has joined
the Company as Chief Executive Officer.

Ms. Fisher was previously Chief Operating Officer at Acorda
Therapeutics, a biotechnology company focused on developing products
for the treatment of central nervous system disorders. During her
seven years at Acorda, she also served as Executive Vice President of
Commercial Operations and Vice President of Marketing and Strategic
Planning. As Chief Operating Officer, she played a key role in
Acorda's success, including its successful IPO and the subsequent
strong operating performance and impressive growth in shareholder
value. Prior to Acorda, Mary was VP, Commercial Operations with
Cephalon. Her earlier career includes positions with Immunex and
Boehringer Ingelheim.

Rex Bright, the current President and CEO of SkinMedica,
commented, "I'm delighted to welcome Mary to SkinMedica. She brings an
impressive track record of accomplishment, with over 25 years of
pharmaceutical and biotechnology industry experience. Mary is ideally
suited to lead SkinMedica's continued growth and development in the
rapidly expanding dermatology and skincare markets. I look forward to
working closely with her to achieve these objectives." Mr. Bright will
continue as President of SkinMedica, and a member of the Board of
Directors, and will also consult closely with Ms. Fisher.

"I am excited by the opportunity to lead SkinMedica. I am
extremely impressed by the quality of their pharmaceutical and
aesthetic products, which are backed by strong science and solid
clinical data," said Ms. Fisher. "The Company already has a very
strong management team, and I look forward working closely with them
to help grow SkinMedica into one of the major dermatology and skincare
companies worldwide."

David F. Hale, SkinMedica's Executive Chairman, stated, "Mary's
leadership and entrepreneurial skills, together with her long record
of success in this industry, will serve SkinMedica well. We are
confident that under Mary's leadership we can continue to build one of
the leading companies in our field."

About SkinMedica

SkinMedica is a privately held pharmaceutical company marketing
both prescription and aesthetic dermatology products. SkinMedica's
Desonate(R) (desonide) Gel 0.05% is indicated for the treatment of
mild to moderate atopic dermatitis; EpiQuin(R) Micro (4% hydroquinone)
cream is indicated for melasma and postinflammatory hyperpigmentation;
VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, is the only
FDA-approved prescription product for the treatment of unwanted facial
hair in women; and NeoBenz(R) Micro Cream and NeoBenz(R) Micro SD
(single dose) are the only benzoyl peroxide prescription products that
contain a patented gradual-release formulation of benzoyl peroxide to
treat acne. The company's full line of physician-dispensed skin care
products includes TNS Recovery Complex(R) with NouriCel-MD(R) to help
improve the health and appearance of aging skin. SkinMedica is based
in Carlsbad, California. For more information, visit
www.skinmedica.com.

SkinMedica(R), Desonate(R), EpiQuin(R) Micro, NeoBenz(R) Micro,
NouriCel-MD(R), TNS Recovery Complex(R), and VANIQA(R) are registered
trademarks of SkinMedica, Inc.

SkinMedica, Inc.
Christina Balesteri, Human Resources
760-448-3622

Copyright Business Wire 2008